Background: Drug development for Alzheimer disease (AD) is challenged by the success in animal models tested in the Morris water maze (MWM) and the subsequent failures to meet primary outcome measures in phase II or III clinical trials in patients. The human variant of MWM (hMWM) enables us to examine allocentric and egocentric navigation as in the MWM. Objective: It was the aim of this study to examine the utility of a computerized hMWM to assess the effects of donepezil in mild AD. Methods: Donepezil 5 mg/day was started after initial hMWM testing in the treated group (n = 12), and after 28 days, the dose was increased to 10 mg/day. The performance after 3 months was compared to that of a non-treated group (n = 12). Results: Donepezil stabilized or improved the spatial navigation performance after 3 months, especially in the allocentric delayed recall subtask (p = 0.014). Conclusions: The computerized hMWM has the potential to measure the effects of donepezil in mild AD. It is a sensitive cognitive outcome measure in AD clinical trials.

1.
Green R, Schneider L, Amato D, Beelen A, Wilcock G, Swabb E, Zavitz K, Tarenflurbil Phase 3 Study Group: Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 2009;302:2557-2564.
2.
Kukar T, Prescott S, Eriksen JL, Holloway V, Murphy MP, Koo EH, Golde TE, Nicolle MM: Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci 2007;8:54.
3.
Morris RG, Garrud P, Rawlins JN, O'Keefe J: Place navigation impaired in rats with hippocampal lesions. Nature 1982;297:681-683.
4.
Hort J, Laczó J, Vyhnálek M, Bojar M, Bureš J, Vlček K: Spatial navigation deficit in amnestic mild cognitive impairment. Proc Natl Acad Sci USA 2007;104:4042-4047.
5.
Hort J, Glosová L, Vyhnálek M, et al: The liquor tau protein and beta amyloid in Alzheimer's disease. Cesk Slov Neurol N 2007;70:30-36.
6.
Laczó J, Vlček K, Vyhnálek M, Vajnerová O, Ort M, Holmerová I, Tolar M, Andel R, Bojar M, Hort J: Spatial navigation testing discriminates two types of amnestic mild cognitive impairment. Behav Brain Res 2009;202:252-259.
7.
Laczó J, Andel R, Vyhnálek M, Vlček K, Magerová H, Varjassyová A, Nedelská Z, Gažová I, Bojar M, Sheardová K, Hort J: From Morris Water Maze to computer tests in the prediction of Alzheimer's disease. Neurodegener Dis 2012;10:153-157.
8.
Laczó J, Andel R, Vlček K, Macoška V, Vyhnálek M, Tolar M, Bojar M, Hort J: Spatial navigation and APOE in amnestic mild cognitive impairment. Neurodegener Dis 2011;8:169-177.
9.
Nedelská Z, Andel R, Laczó J, Vlček K, Hořínek D, Lisý J, Sheardová K, Bureš J, Hort J: Spatial navigation impairment is proportional to right hippocampal volume. Proc Natl Acad Sci USA 2012;109:2590-2594.
10.
Berger-Sweeney J, Stearns N, Murg S, Floerke-Nashner L, Lappi D, Baxter M: Selective immunolesions of cholinergic neurons in mice: effects on neuroanatomy, neurochemistry, and behavior. J Neurosci 2001;21:8164-8173.
11.
Grön G, Brandenburg I, Wunderlich A, Riepe M: Inhibition of hippocampal function in mild cognitive impairment: targeting the cholinergic hypothesis. Neurobiol Aging 2006;27:78-87.
12.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
13.
Birks J, Harvey R: Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2006;1:CD001190.
14.
Laczó J, Andel R, Vlček K, Vyhnálek M, Gažová I, Nedelská Z, Mokrišová I, Hynčicová E, Literáková E, Sheardová K, Wagner M, Coulson EJ, Hort J: Spatial navigation in the real world is a separate cognitive domain: study on cognitively normal elderly and mild cognitive impairment. Neurodegener Dis 2013, in press.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.